Sunny Pharmtech Statistics
Total Valuation
Sunny Pharmtech has a market cap or net worth of TWD 2.03 billion. The enterprise value is 2.39 billion.
Market Cap | 2.03B |
Enterprise Value | 2.39B |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
Earnings Date | Nov 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Sunny Pharmtech has 148.82 million shares outstanding. The number of shares has increased by 0.66% in one year.
Current Share Class | 148.82M |
Shares Outstanding | 148.82M |
Shares Change (YoY) | +0.66% |
Shares Change (QoQ) | +0.03% |
Owned by Insiders (%) | 17.79% |
Owned by Institutions (%) | 3.56% |
Float | 105.34M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 7.00 |
PB Ratio | 2.27 |
P/TBV Ratio | 2.43 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -8.87 |
EV / Sales | 8.24 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -16.40 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.49.
Current Ratio | 1.30 |
Quick Ratio | 0.55 |
Debt / Equity | 0.49 |
Debt / EBITDA | n/a |
Debt / FCF | -3.00 |
Interest Coverage | -26.09 |
Financial Efficiency
Return on equity (ROE) is -26.20% and return on invested capital (ROIC) is -10.98%.
Return on Equity (ROE) | -26.20% |
Return on Assets (ROA) | -10.05% |
Return on Invested Capital (ROIC) | -10.98% |
Return on Capital Employed (ROCE) | -20.38% |
Revenue Per Employee | 1.84M |
Profits Per Employee | -1.71M |
Employee Count | 154 |
Asset Turnover | 0.18 |
Inventory Turnover | 1.16 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.03% in the last 52 weeks. The beta is -0.03, so Sunny Pharmtech's price volatility has been lower than the market average.
Beta (5Y) | -0.03 |
52-Week Price Change | -42.03% |
50-Day Moving Average | 16.86 |
200-Day Moving Average | 16.98 |
Relative Strength Index (RSI) | 26.92 |
Average Volume (20 Days) | 256,686 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sunny Pharmtech had revenue of TWD 290.18 million and -269.51 million in losses. Loss per share was -1.82.
Revenue | 290.18M |
Gross Profit | 155.48M |
Operating Income | -254.01M |
Pretax Income | -269.51M |
Net Income | -269.51M |
EBITDA | -137.79M |
EBIT | -254.01M |
Loss Per Share | -1.82 |
Balance Sheet
The company has 77.93 million in cash and 437.79 million in debt, giving a net cash position of -359.86 million or -2.42 per share.
Cash & Cash Equivalents | 77.93M |
Total Debt | 437.79M |
Net Cash | -359.86M |
Net Cash Per Share | -2.42 |
Equity (Book Value) | 894.85M |
Book Value Per Share | 6.01 |
Working Capital | 74.91M |
Cash Flow
In the last 12 months, operating cash flow was -112.58 million and capital expenditures -33.23 million, giving a free cash flow of -145.81 million.
Operating Cash Flow | -112.58M |
Capital Expenditures | -33.23M |
Free Cash Flow | -145.81M |
FCF Per Share | -0.98 |
Margins
Gross margin is 53.58%, with operating and profit margins of -87.53% and -92.88%.
Gross Margin | 53.58% |
Operating Margin | -87.53% |
Pretax Margin | -92.88% |
Profit Margin | -92.88% |
EBITDA Margin | -47.48% |
EBIT Margin | -87.53% |
FCF Margin | n/a |
Dividends & Yields
Sunny Pharmtech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.66% |
Shareholder Yield | -0.66% |
Earnings Yield | -13.27% |
FCF Yield | -7.18% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Sunny Pharmtech has an Altman Z-Score of 2.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.24 |
Piotroski F-Score | 2 |